These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 3484628)
21. Sodium diethyldithiocarbamate protects against the MPTP-induced inhibition of immune responses in mice. Renoux G; Bizière K; Renoux M; Steinberg R; Kan JP; Guillaumin JM Life Sci; 1989; 44(12):771-7. PubMed ID: 2539542 [TBL] [Abstract][Full Text] [Related]
22. Characterization of hepatic microsomal metabolism as an in vivo detoxication pathway of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Chiba K; Kubota E; Miyakawa T; Kato Y; Ishizaki T J Pharmacol Exp Ther; 1988 Sep; 246(3):1108-15. PubMed ID: 3262153 [TBL] [Abstract][Full Text] [Related]
23. Repeated administration of N-methyl-4-phenyl 1,2,5,6-tetrahydropyridine to rats is not toxic to striatal dopamine neurones. Boyce S; Kelly E; Reavill C; Jenner P; Marsden CD Biochem Pharmacol; 1984 Jun; 33(11):1747-52. PubMed ID: 6610420 [TBL] [Abstract][Full Text] [Related]
24. Treatment with GM1 ganglioside restores striatal dopamine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse. Hadjiconstantinou M; Neff NH J Neurochem; 1988 Oct; 51(4):1190-6. PubMed ID: 3262149 [TBL] [Abstract][Full Text] [Related]
26. Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice. D'Astous M; Morissette M; Tanguay B; Callier S; Di Paolo T Synapse; 2003 Jan; 47(1):10-4. PubMed ID: 12422368 [TBL] [Abstract][Full Text] [Related]
27. Oral versus parenteral efficacy of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): differential effects on depletion of heart norepinephrine and of striatal dopamine in mice. Fuller RW; Hemrick-Luecke SK Biochem Pharmacol; 1987 Mar; 36(6):789-92. PubMed ID: 3494450 [No Abstract] [Full Text] [Related]
28. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) does not destroy nigrostriatal neurons in the scorbutic guinea pig. Perry TL; Yong VW; Ito M; Jones K; Wall RA; Foulks JG; Wright JM; Kish SJ Life Sci; 1985 Apr; 36(13):1233-8. PubMed ID: 2858797 [TBL] [Abstract][Full Text] [Related]
29. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Sonsalla PK; Heikkila RE Eur J Pharmacol; 1986 Oct; 129(3):339-45. PubMed ID: 3490988 [TBL] [Abstract][Full Text] [Related]
30. Effect of amphetamine on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice. Sershen H; Mason MF; Reith ME; Hashim A; Lajtha A Neuropharmacology; 1986 Aug; 25(8):927-30. PubMed ID: 3490630 [TBL] [Abstract][Full Text] [Related]
32. Relation between brain dopamine loss and D2 dopamine receptor density in MPTP monkeys. Falardeau P; Bédard PJ; Di Paolo T Neurosci Lett; 1988 Mar; 86(2):225-9. PubMed ID: 2966905 [TBL] [Abstract][Full Text] [Related]
33. Chronic L-deprenyl does not alter the restoration of striatal dopamine in MPTP-lesioned mice. Wiener HL; Hashim A; Lajtha A; Sershen H J Neurosci Res; 1989 Jul; 23(3):326-9. PubMed ID: 2504936 [TBL] [Abstract][Full Text] [Related]
34. Increased striatal dopamine turnover following acute administration of rotenone to mice. Thiffault C; Langston JW; Di Monte DA Brain Res; 2000 Dec; 885(2):283-8. PubMed ID: 11102582 [TBL] [Abstract][Full Text] [Related]
35. [Study of extracellular concentration of dopamine and its metabolites in mice striatum by a microdialysis technique at intraperitoneal administration of MPTP]. Averkin RG; Korshunov VA; Shchegolevskiĭ NV; Mats VN; Markevich VA; Grigor'ian GA; Bazian AS Zh Vyssh Nerv Deiat Im I P Pavlova; 2010; 60(1):109-19. PubMed ID: 20352690 [TBL] [Abstract][Full Text] [Related]
36. Biochemical and functional evidence for a marked dopamine releasing action of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (NMPTP) in mouse brain. Pileblad E; Nissbrandt H; Carlsson A J Neural Transm; 1984; 60(3-4):199-203. PubMed ID: 6084705 [TBL] [Abstract][Full Text] [Related]
37. Endogenous analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: indoleamine derived tetrahydro-beta-carbolines as potential causative factors in Parkinson's disease. Collins MA; Neafsey EJ; Cheng BY; Hurley-Gius K; Ung-Chhun NA; Pronger DA; Christensen MA; Hurley-Gius D Adv Neurol; 1987; 45():179-82. PubMed ID: 3493625 [No Abstract] [Full Text] [Related]
38. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Heikkila RE; Manzino L; Cabbat FS; Duvoisin RC Nature; 1984 Oct 4-10; 311(5985):467-9. PubMed ID: 6332989 [TBL] [Abstract][Full Text] [Related]
39. Oral administration of semisynthetic sphingolipids promotes recovery of striatal dopamine concentrations in a murine model of parkinsonism. Schneider JS; DiStefano L Neurology; 1994 Apr; 44(4):748-50. PubMed ID: 8164837 [TBL] [Abstract][Full Text] [Related]
40. Differential effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the olfactory bulb and the striatum in mice. Mitsumoto Y; Mori A; Ohashi S; Nakai M; Moriizumi T Neurosci Res; 2005 Jan; 51(1):111-5. PubMed ID: 15596247 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]